Metabotropic glutamate receptor 5 in bulimia nervosa

Mihov, Yoan; Treyer, Valerie; Akkus, Funda; Toman, Erika; Milos, Gabriella; Ametamey, Simon M.; Johayem, Anass; Hasler, Gregor

doi:10.1038/s41598-020-63389-7

Back

Journal article

+ 1 other files

Metabotropic glutamate receptor 5 in bulimia nervosa

Mihov, Yoan Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland - Psychiatry Research Unit, University of Fribourg, Chemin du Cardinal-Journet 3, 1752, Villars-sur-Glâne, Switzerland
Treyer, Valerie Departement of Nuclear Medicine, University Hospital Zürich, University of Zürich, 8091, Zürich, Switzerland
Akkus, Funda Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland
Toman, Erika Competence Network for Eating Disorders, Forchstrasse 132, 8032, Zürich, Switzerland
Milos, Gabriella Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zürich, Culmannstrasse 8, 8091, Zürich, Switzerland
Ametamey, Simon M. Center for Radiopharmaceutical Science of ETH, PSI, and USZ, Department of Chemistry and Applied Biosciences of ETH, 8093, Zürich, Switzerland
Johayem, Anass Departement of Nuclear Medicine, University Hospital Zürich, University of Zürich, 8091, Zürich, Switzerland
Hasler, Gregor Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland - Psychiatry Research Unit, University of Fribourg, Chemin du Cardinal-Journet 3, 1752, Villars-sur-Glâne, Switzerland

14.04.2020

Published in:

Scientific Reports. - 2020, vol. 10, no. 1, p. 6374

English Bulimia nervosa (BN) shares central features with substance-related and addictive disorders. The metabotropic glutamate receptor subtype 5 (mGlu5) plays an important role in addiction. Based on similarities between binge eating and substance-related and addictive disorders, we investigated mGlu5 in vivo in 15 female subjects with BN and 15 matched controls. We measured mGlu5 distribution volume ratio (DVR) with positron emission tomography (PET) using [11 C]ABP688. In BN mGlu5 DVR was higher in the anterior cingulate cortex (ACC), subgenual prefrontal cortex, and straight gyrus (p < 0.05). In BN, higher mGlu5 DVR in various brain regions, including ACC, pallidum, putamen, and caudate, positively correlated with “maturity fears” as assessed using the Eating Disorder Inventory-2 (p < 0.05). In BN and controls, smokers had globally decreased mGlu5 DVR. We present the first evidence for increased mGlu5 DVR in BN. Our findings suggest that pharmacological agents inhibiting mGlu5 might have a therapeutic potential in BN.

Faculty

Faculté des sciences et de médecine

Department

Master en médecine

Language